Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSC (BP CC 001) for Cartilage Damage in the Knee Joint
2024-517684-23-00Phase 2Authorised
- Sponsor
- BIONCaRT
- Start
- Apr 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of umbilical cord tissue-derived mesenchymal stromal cells in cartilage defect of knee, sponsored by BIONCaRT. Primary endpoint: Proportion of patients with a serious adverse event within 24 months after surgery. Planned start Apr 2025; status: authorised.
02
Drugs
umbilical cord tissue-derived mesenchymal stromal cells
03
Conditions
cartilage defect of knee
Beyond the preview
Go deeper on 2024-517684-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517684-23-00.